Page 91 - 80_01

Los
medicamentos
de
origen
biotecnológico…

70.
Bhamidipati
PK,
Kantarjian
H,
Cortes
J,
Cornelison
AM,
Jabbour
E.
Management
of
imatinib-­-
resistant
patients
with
chronic
myeloid
leukemia.
Ther
Adv
Hematol
4(2),
103-­-17
(2013).

71.
Breccia
M,
Alimena
G.
Second-­-generation
tyrosine
kinase
inhibitors
as
first-­-line
treatment

strategy
in
newly
diagnosed
chronic
phase
chronic
myeloid
leukemia
patients.
Curr

Cancer
Drug
Targets
12(4),
391-­-401
(2012).

72.
Mealing
S,
Barcena
L,
Hawkins
N,
Clark
J,
Eaton
V,
Hirji
I,
et
al.
The
relative
efficacy
of

imatinib,
dasatinib
and
nilotinib
for
newly
diagnosed
chronic
myeloid
leukemia:
a

systematic
review
and
network
meta-­-analysis.
Exp
Hematol
Oncol
2(1),
5
(2013).

73.
Breccia
M,
Salaroli
A,
Molica
M,
Alimena
G.
Systematic
review
of
dasatinib
in
chronic

myeloid
leukemia.
Onco
Targets
Ther
6,
257-­-65
(2013).

74.
Piccaluga
PP,
Paolini
S,
Bertuzzi
C,
De
Leo
A,
Rosti
G.
First-­-line
treatment
of
chronic

myeloid
leukemia
with
nilotinib:
critical
evaluation.
J
Blood
Med
3,
151-­-6
(2012).

75.
Awad
MM,
Katayama
R,
McTigue
M,
Liu
W,
Deng
YL,
Brooun
A,
et
al.
Acquired
Resistance
to

Crizotinib
from
a
Mutation
in
CD74-­-ROS1.
N
Engl
J
Med
368(25),
2395-­-401
(2013).

76.
Roberts
PJ.
Clinical
use
of
crizotinib
for
the
treatment
of
non-­-small
cell
lung
cancer.

Biologics
7,
91-­-101
(2013).

77.
Pennell
NA.
Treating
Anaplastic
Lymphoma
Kinase-­-Positive
Lung
Cancer
in
the
Weeks

After
the
US
Food
and
Drug
Administration
Approval
of
Crizotinib.
J
Oncol
Pract
8(3

Suppl),
34s-­-7s
(2012).

78.
Rajendra
R,
Jones
RL,
Pollack
SM.
Targeted
treatment
for
advanced
soft
tissue
sarcoma:

profile
of
pazopanib.
Onco
Targets
Ther
6,
217-­-22
(2013).

79.
Heudel
P,
Cassier
P,
Derbel
O,
Dufresne
A,
Meeus
P,
Thiesse
P,
et
al.
Pazopanib
for
the

treatment
of
soft-­-tissue
sarcoma.
Clin
Pharmacol
4,
65-­-70
(2012).

80.
Harrison
C,
Vannucchi
AM.
Ruxolitinib:
a
potent
and
selective
Janus
kinase
1
and
2

inhibitor
in
patients
with
myelofibrosis.
An
update
for
clinicians.
Ther
Adv
Hematol
3(6),

341-­-54
(2012).

81.
Gu
L,
Su
L,
Chen
Q,
Xie
J,
Wu
G,
Yan
Y,
et
al.
Ruxolitinib
for
myelofibrosis.
Exp
Ther
Med

5(3),
927-­-931
(2013).

82.
Cohen
GS,
Black
M.
Multidisciplinary
management
of
hepatocellular
carcinoma:
a
model
for

therapy.
J
Multidiscip
Healthc
6,
189-­-95
(2013).

83.
Wang
Z,
Wu
XL,
Zeng
WZ,
Xu
GS,
Xu
H,
Weng
M,
et
al.
Meta-­-analysis
of
the
Efficacy
of

Sorafenib
for
Hepatocellular
Carcinoma.
Asian
Pac
J
Cancer
Prev
14(2),
691-­-4
(2013).

84.
Amsberg
GK,
Schafhausen
P.
Bosutinib
in
the
management
of
chronic
myelogenous

leukemia.
Biologics
7,
115-­-22
(2013).

85.
Menaa
F.
Latest
approved
therapies
for
metastatic
melanoma:
what
comes
next?
J
Skin

Cancer
2013,
735282
(2013).

86.
Sapkota
B,
Hill
CE,
Pollack
BP.
Vemurafenib
enhances
MHC
induction
in
BRAF(V600E)

homozygous
melanoma
cells.
Oncoimmunology
2(1),
e22890
(2013).

87.
Vergnenègre
A,
Borget
I,
Chouaid
C.
Update
on
the
treatment
of
non-­-small-­-cell
lung
cancer:

focus
on
the
cost-­-effectiveness
of
new
agents.
Clinicoecon
Outcomes
Res
5,
137-­-41
(2013).

88.
Chen
X,
Liu
Y,
Røe
OD,
Qian
Y,
Guo
R,
Zhu
L,
et
al.
Gefitinib
or
Erlotinib
as
Maintenance

Therapy
in
Patients
with
Advanced
Stage
Non-­-Small
Cell
Lung
Cancer:
A
Systematic

Review.
PLoS
ONE

8(3),
e59314
(2013).

89.
Sonoda
H,
Mekata
E,
Shimizu
T,
Endo
Y,
Tani
T.
Safety
and
efficacy
of
panitumumab

therapy
after
metastatic
colorectal
cancer
progression
with
cetuximab:
Experience
at
a

single
Japanese
institution.
Oncol
Lett
5(4),
1331-­-34
(2013).

90.
Muhammad
S,
Jiang
Z,
Liu
Z,
Kaur
K,
Wang
X.
The
role
of
EGFR
monoclonal
antibodies

(MoABs)
cetuximab/panitumab,
and
BRAF
inhibitors
in
BRAF
mutated
colorectal
cancer.
J

Gastrointest
Oncol
4(1),
72-­-81
(2013).

91.
Niedzwiecki
D,
Bertagnolli
MM,
Warren
RS,
Compton
CC,
Kemeny
NE,
Benson
AB
3rd,
et
al.

Documenting
the
natural
history
of
patients
with
resected
stage
II
adenocarcinoma
of
the

colon
after
random
assignment
to
adjuvant
treatment
with
edrecolomab
or
observation:

results
from
CALGB
9581.
J
Clin
Oncol
29(23),
3146-­-52
(2011).

92.
Zhao
L,
He
LR,
Xi
M,
Cai
MY,
Shen
JX,
Li
QQ,
et
al.
Nimotuzumab
promotes
radiosensitivity

of
EGFR-­-overexpression
esophageal
squamous
cell
carcinoma
cells
by
upregulating
IGFBP-­-
3.
J
Transl
Med
10,
249
(2012).

93.
Perez
R,
Crombet
T,
de
Leon
J,
Moreno
E.
A
view
on
EGFR-­-targeted
therapies
from
the

oncogene-­-addiction
perspective.
Front
Pharmacol
4,
53
(2013).

89